Login / Signup

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.

Naga P ChalasaniEduardo Vilar-GomezStephen CaldwellKatherine P YatesAnna Mae DiehlBrent A Neuschwander-TetriSrinivasan DasarathyKris V KowdleyNorah A TerraultLaura A WilsonJames TonasciaArun J Sanyal
Published in: Hepatology (Baltimore, Md.) (2024)
The deleterious effects of PNPLA3 rs738409 on the risk of MALO are significantly worsened by AF, age, type 2 diabetes mellitus, and sex.
Keyphrases
  • glycemic control
  • type diabetes
  • cardiovascular disease
  • atrial fibrillation
  • oxidative stress
  • cardiovascular risk factors
  • skeletal muscle
  • adverse drug
  • liver fibrosis
  • drug induced